ticker,event_date,window_start,window_end,symbol,symbols,publishedDate,publishedDateET,date_et,title,text,site,url,image
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-01 14:08:24,2024-10-01T14:08:24-04:00,2024-10-01,J&J to invest more than $2 billion in new manufacturing facility,"Johnson & Johnson said on Tuesday it will invest more than $2 billion to build a new manufacturing facility at Wilson, North Carolina.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/jj-invest-more-than-2-billion-new-manufacturing-facility-2024-10-01/,https://images.financialmodelingprep.com/news/jj-to-invest-more-than-2-billion-in-new-20241001.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-02 09:00:00,2024-10-02T09:00:00-04:00,2024-10-02,ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer,"Largest head-to-head real-world study in mCSPC demonstrated that ERLEADA® reduced risk of death by 23 percent at 24 months compared to enzalutamide LISBON, Portugal , Oct. 2, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the results of a landmark real-world, head-to-head study showing that ERLEADA® (apalutamide) provided a statistically significant overall survival benefit at 24 months compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC). Presented at the 6th European Congress of Oncology Pharmacy (ECOP) in Lisbon, Portugal, on October 2 (Abstract #P31), this study of nearly 4,000 patients represents the largest real-world, head-to-head analysis of these two androgen receptor pathway inhibitors (ARPIs) in mCSPC.",prnewswire.com,https://www.prnewswire.com/news-releases/erleada-apalutamide-demonstrates-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-compared-to-enzalutamide-in-patients-with-metastatic-castration-sensitive-prostate-cancer-302265567.html,https://images.financialmodelingprep.com/news/erleada-apalutamide-demonstrates-statistically-significant-and-clinically-meaningful-improvement-20241002.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-03 18:51:23,2024-10-03T18:51:23-04:00,2024-10-03,Why Johnson & Johnson (JNJ) Dipped More Than Broader Market Today,"Johnson & Johnson (JNJ) concluded the recent trading session at $160.50, signifying a -0.42% move from its prior day's close.",zacks.com,https://www.zacks.com/stock/news/2345682/why-johnson-johnson-jnj-dipped-more-than-broader-market-today?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_6-2345682,https://images.financialmodelingprep.com/news/why-johnson-johnson-jnj-dipped-more-than-broader-market-20241003.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-04 16:30:00,2024-10-04T16:30:00-04:00,2024-10-04,Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference,"NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Guggenheim Global Healthcare Conference on Tuesday, November 12th, at the InterContinental Boston in Boston, MA. Biljana Naumovic, President, Solid Tumor, U.S. Oncology and Mark Wildgust, Vice President, Global Medical Affairs Oncology, will represent the Company in a session scheduled at 10:30 a.m. (Eastern Time). This live audio webcast will be available to investors and other interested parties by.",businesswire.com,https://www.businesswire.com/news/home/20241004735017/en/Johnson-Johnson-to-Participate-in-the-Guggenheim-Global-Healthcare-Conference/,https://images.financialmodelingprep.com/news/johnson-johnson-to-participate-in-the-guggenheim-global-healthcare-20241004.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-04 13:37:00,2024-10-04T13:37:00-04:00,2024-10-04,Chicago Court Upholds $45 Million Mesothelioma Verdict Against Johnson & Johnson,"CHICAGO--(BUSINESS WIRE)--A Circuit Court in Cook County, Ill., has denied a request by Johnson & Johnson (NYSE:JNJ) for a new trial in a mesothelioma lawsuit decided in April, upholding a jury verdict and award of $45 million in the asbestos-related death of a mother of six. Johnson & Johnson raised multiple issues in its motion for a new trial, but in each case, the court either found for the plaintiff or determined that any issue did not substantially prejudice the jury. The decision.",businesswire.com,https://www.businesswire.com/news/home/20241004348565/en/Chicago-Court-Upholds-45-Million-Mesothelioma-Verdict-Against-Johnson-Johnson/,https://images.financialmodelingprep.com/news/chicago-court-upholds-45-million-mesothelioma-verdict-against-johnson-20241004.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-04 09:19:47,2024-10-04T09:19:47-04:00,2024-10-04,Johnson & Johnson discontinues dengue drug study,Johnson & Johnson said on Friday it will discontinue its mid-stage field study evaluating the efficacy of its antiviral drug candidate for the prevention of dengue.,reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/johnson-johnson-discontinues-dengue-drug-study-2024-10-04/,https://images.financialmodelingprep.com/news/johnson-johnson-discontinues-dengue-drug-study-20241004.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-04 08:00:00,2024-10-04T08:00:00-04:00,2024-10-04,Stock Picks From Seeking Alpha's September 2024 New Analysts,"In September, thirty new analysts joined Seeking Alpha, offering diverse stock picks and insights, from Strong Buy to Strong Sell ratings. Highlighted picks include InMode Ltd., Intel Corporation, and iShares 20+ Year Treasury Bond ETF, each with unique investment theses and strong buy ratings. Analysts' backgrounds range from software engineering to finance, enhancing their stock research with diverse perspectives and methodologies.",seekingalpha.com,https://seekingalpha.com/article/4724910-stock-picks-from-seeking-alphas-september-2024-new-analysts,https://images.financialmodelingprep.com/news/stock-picks-from-seeking-alphas-september-2024-new-analysts-20241004.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-04 05:20:00,2024-10-04T05:20:00-04:00,2024-10-04,2 Smart Income Stocks to Buy Right Now,These storied companies have a lot to offer different investors.,fool.com,https://www.fool.com/investing/2024/10/04/2-smart-income-stocks-to-buy-right-now/,https://images.financialmodelingprep.com/news/2-smart-income-stocks-to-buy-right-now-20241004.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-05 09:00:00,2024-10-05T09:00:00-04:00,2024-10-05,5 Relatively Secure And Cheap Dividend Stocks To Invest In -- October 2024,"This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields about 3.4%, we present two other groups of five DGI stocks each, with the goal of moderate to high yields.",seekingalpha.com,https://seekingalpha.com/article/4724608-5-relatively-secure-and-cheap-dividend-stocks-to-invest-in-october-2024,https://images.financialmodelingprep.com/news/5-relatively-secure-and-cheap-dividend-stocks-to-invest-20241005.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-05 02:38:45,2024-10-05T02:38:45-04:00,2024-10-05,Buy 2 October Dogs Of The Dow And Watch 5 More,"""The Dow® [adds a stock] if the company has an excellent reputation,",seekingalpha.com,https://seekingalpha.com/article/4725144-buy-2-october-dogs-of-dow-watch-5-more,https://images.financialmodelingprep.com/news/buy-2-october-dogs-of-the-dow-and-watch-20241005.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-07 16:40:33,2024-10-07T16:40:33-04:00,2024-10-07,J&J discontinues late-stage study for bladder cancer drug,Johnson & Johnson said on Monday it has discontinued a late-stage study testing its experimental drug to treat a type of bladder cancer as the drug did not show superior benefits compared to chemoradiation.,reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/jj-discontinues-late-stage-study-bladder-cancer-drug-2024-10-07/,https://images.financialmodelingprep.com/news/jj-discontinues-latestage-study-for-bladder-cancer-drug-20241007.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-07 16:01:10,2024-10-07T16:01:10-04:00,2024-10-07,Should JNJ Stock Be in Your Portfolio Ahead of Q3 Earnings?,JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. It remains to be seen if MedTech sales improved.,zacks.com,https://www.zacks.com/stock/news/2347080/should-jnj-stock-be-in-your-portfolio-ahead-of-q3-earnings?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_preview-2347080,https://images.financialmodelingprep.com/news/should-jnj-stock-be-in-your-portfolio-ahead-of-20241007.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-07 14:01:10,2024-10-07T14:01:10-04:00,2024-10-07,Johnson & Johnson Scraps Phase II Study on Antiviral for Dengue Virus,"As part of the strategic re-prioritization, JNJ terminates the phase II field study on mosnodenvir for the prevention of the dengue virus.",zacks.com,https://www.zacks.com/stock/news/2347027/johnson-johnson-scraps-phase-ii-study-on-antiviral-for-dengue-virus?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2347027,https://images.financialmodelingprep.com/news/johnson-johnson-scraps-phase-ii-study-on-antiviral-for-20241007.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-07 08:16:20,2024-10-07T08:16:20-04:00,2024-10-07,Top 3 Risk-Averse Stocks to Add Stability to Your Portfolio,"While some investors relish the thrill of high-growth ventures with the potential for significant returns, others prioritize capital preservation and seek out investments that offer security and stability. This approach, known as risk aversion, is a core concept for investors seeking to minimize portfolio volatility and protect their principal investment.",marketbeat.com,https://www.marketbeat.com/stock-ideas/top-3-risk-averse-stocks-to-add-stability-to-your-portfolio/,https://images.financialmodelingprep.com/news/top-3-riskaverse-stocks-to-add-stability-to-your-20241007.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-07 07:02:53,2024-10-07T07:02:53-04:00,2024-10-07,3 Undervalued Dividend Stocks Primed for Growth in 2025,"In volatile markets, investors are often reminded of the relative security in dividend stocks. These are considered safe havens that can help you generate strong long-term returns.",marketbeat.com,https://www.marketbeat.com/stock-ideas/3-undervalued-dividend-stocks-primed-for-growth-in-2025/,https://images.financialmodelingprep.com/news/3-undervalued-dividend-stocks-primed-for-growth-in-2025-20241007.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-08 20:50:30,2024-10-08T20:50:30-04:00,2024-10-08,Should Investors Consider High Yield Dividend Stocks?,"When selecting dividend-paying stocks, one of the first things that investors look at is, of course, the annual yield.",zacks.com,https://www.zacks.com/stock/news/2347905/should-investors-consider-high-yield-dividend-stocks?cid=CS-STOCKNEWSAPI-FT-stocks_in_the_news-2347905,https://images.financialmodelingprep.com/news/should-investors-consider-high-yield-dividend-stocks-20241008.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-08 14:00:05,2024-10-08T14:00:05-04:00,2024-10-08,What To Expect When Johnson & Johnson Reports Q3 Earnings Next Week?,"Monday, Johnson & Johnson JNJ said it discontinued the Phase 3 SunRISe-2 trial of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy for muscle-invasive urothelial carcinoma (MIBC) patients who are not receiving radical cystectomy.",benzinga.com,https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41236724/what-to-expect-when-johnson-johnson-reports-q3-earnings-next-week,https://images.financialmodelingprep.com/news/what-to-expect-when-johnson-johnson-reports-q3-earnings-20241008.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-08 11:08:29,2024-10-08T11:08:29-04:00,2024-10-08,Analysts Estimate Johnson & Johnson (JNJ) to Report a Decline in Earnings: What to Look Out for,Johnson & Johnson (JNJ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,zacks.com,https://www.zacks.com/stock/news/2347550/analysts-estimate-johnson-johnson-jnj-to-report-a-decline-in-earnings-what-to-look-out-for?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_9-2347550,https://images.financialmodelingprep.com/news/analysts-estimate-johnson-johnson-jnj-to-report-a-decline-20241008.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-08 09:00:00,2024-10-08T09:00:00-04:00,2024-10-08,Undervalued Dividend Kings: October 2024,"Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges. I rank Dividend Kings by quality score and highlight undervalued stocks for potential investment. The article provides tables and charts presenting quality scores, key metrics, and fair value estimates.",seekingalpha.com,https://seekingalpha.com/article/4725491-undervalued-dividend-kings-october-2024,https://images.financialmodelingprep.com/news/undervalued-dividend-kings-october-2024-20241008.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-08 02:50:52,2024-10-08T02:50:52-04:00,2024-10-08,"Johnson & Johnson (JNJ) Halts TAR-200 Bladder Cancer Trial, Future FDA Plans Remain","Johnson & Johnson (JNJ, Financial) has announced the termination of its phase 2 trial for the TAR-200 therapy aimed at treating patients with muscle-invasive bladder cancer (MIBC). The decision followed an interim analysis from the SunRISe-2 study, which indicated no advantage over existing chemo-radiation treatments.",gurufocus.com,https://www.gurufocus.com/news/2544335/johnson--johnson-jnj-halts-tar200-bladder-cancer-trial-future-fda-plans-remain,https://images.financialmodelingprep.com/news/johnson-johnson-jnj-halts-tar200-bladder-cancer-trial-future-20241008.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-09 12:17:05,2024-10-09T12:17:05-04:00,2024-10-09,Buy 4 October Dividend Aristocrats & Watch 10,"""Dividend Aristocrats... in the S&P500 Index… have raised their annual payouts every year for at least 25 consecutive years."" -- Kiplinger.com/Investing. 67 Aristocrats, screened as of October 7, 2024 represented all eleven Morningstar Sectors. Broker estimated-top-ten net-gains ranged 10.5%-20.13% topped-by Franklin & Target.",seekingalpha.com,https://seekingalpha.com/article/4725840-buy-4-october-dividend-aristocrats-watch-10,https://images.financialmodelingprep.com/news/buy-4-october-dividend-aristocrats-watch-10-20241009.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-09 11:32:09,2024-10-09T11:32:09-04:00,2024-10-09,Johnson & Johnson (JNJ) Completes Acquisition of V-Wave Ltd for $600 Million,"Johnson & Johnson (JNJ, Financial) has finalized the acquisition of V-Wave Ltd, a private medical device company. The pharmaceutical giant agreed to purchase V-Wave for an upfront payment of $600 million.",gurufocus.com,https://www.gurufocus.com/news/2546111/johnson--johnson-jnj-completes-acquisition-of-vwave-ltd-for-600-million,https://images.financialmodelingprep.com/news/johnson-johnson-jnj-completes-acquisition-of-vwave-ltd-for-20241009.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-09 10:06:33,2024-10-09T10:06:33-04:00,2024-10-09,Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock,"Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",zacks.com,https://www.zacks.com/stock/news/2348084/here-is-what-to-know-beyond-why-johnson-johnson-jnj-is-a-trending-stock?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2348084,https://images.financialmodelingprep.com/news/here-is-what-to-know-beyond-why-johnson-johnson-20241009.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-10 18:16:46,2024-10-10T18:16:46-04:00,2024-10-10,"J&J talc bankruptcy stays in Texas despite 'forum-shopping"" opposition","A Johnson & Johnson subsidiary can pursue its third attempt to resolve tens of thousands of lawsuits alleging its talc products caused cancer in a Texas bankruptcy court, a judge ruled on Thursday, allowing the company to avoid a venue that shot down its two previous efforts.",reuters.com,https://www.reuters.com/legal/jj-talc-bankruptcy-stays-texas-despite-forum-shopping-opposition-2024-10-10/,https://images.financialmodelingprep.com/news/jj-talc-bankruptcy-stays-in-texas-despite-forumshopping-opposition-20241010.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-10 16:30:00,2024-10-10T16:30:00-04:00,2024-10-10,Johnson & Johnson to Participate in the Stifel 2024 Healthcare Conference,"NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will participate in the Stifel 2024 Healthcare Conference on Monday, November 18th, at the Lotte New York Palace in New York. Michael Bodner, Group President, Heart Recovery & Circulatory Restoration, will represent the Company in a session scheduled at 10:55 a.m. (Eastern Time). This live audio webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.inve.",businesswire.com,https://www.businesswire.com/news/home/20241010952721/en/Johnson-Johnson-to-Participate-in-the-Stifel-2024-Healthcare-Conference/,https://images.financialmodelingprep.com/news/johnson-johnson-to-participate-in-the-stifel-2024-healthcare-20241010.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-10 11:10:03,2024-10-10T11:10:03-04:00,2024-10-10,Johnson & Johnson: You Need To Look At This Chart (Rating Upgrade),JNJ's current dividend yield is around the highest level in at least 10 years. The market's concern over its current issues - which are all temporary in my view - is drastically overblown. The overreaction has created a severe mispricing for this sector leader with superb financial strength and stable growth outlook.,seekingalpha.com,https://seekingalpha.com/article/4726000-johnson-and-johnson-you-need-to-look-at-this-chart-rating-upgrade,https://images.financialmodelingprep.com/news/johnson-johnson-you-need-to-look-at-this-chart-20241010.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-10 10:20:26,2024-10-10T10:20:26-04:00,2024-10-10,Johnson & Johnson (JNJ) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates,"Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",zacks.com,https://www.zacks.com/stock/news/2348755/johnson-johnson-jnj-q3-earnings-preview-what-you-should-know-beyond-the-headline-estimates?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm_preview-2348755,https://images.financialmodelingprep.com/news/johnson-johnson-jnj-q3-earnings-preview-what-you-should-20241010.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-10 08:00:00,2024-10-10T08:00:00-04:00,2024-10-10,TREMFYA® (guselkumab) demonstrates impressive results across biologic-naïve and biologic-refractory patients in Crohn's disease and ulcerative colitis,"TREMFYA ®  is now U.S. FDA-approved for ulcerative colitis and under review for Crohn's disease TREMFYA® is the only IL-23 inhibitor to demonstrate superiority to ustekinumab in the overall population of patients with Crohn's disease, inclusive of those who are biologic-naïve and biologic-refractory  Ninety percent more biologic-naïve  patients and three times more biologic-refractory patients with ulcerative colitis achieved endoscopic remission with TREMFYA ®   VIENNA, Austria , Oct. 10, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced TREMFYA® (guselkumab) data in both Crohn's disease (CD) and ulcerative colitis (UC) showing high rates of endoscopic remission in both biologic-naïve and biologic-refractory patients (including UC patients refractory to JAK inhibitors), indicating a normal appearance of intestinal mucosa.1,2 These subgroup analyses are from pooled data from the Phase 3 GALAXI 2 & 3 studies of TREMFYA® in adults with moderately to severely active CD and the Phase 3 QUASAR maintenance study of TREMFYA® in adults with moderately to severely active UC. These findings are among 19 Johnson & Johnson abstracts being presented at the United European Gastroenterology (UEG) Week 2024.",prnewswire.com,https://www.prnewswire.com/news-releases/tremfya-guselkumab-demonstrates-impressive-results-across-biologic-naive-and-biologic-refractory-patients-in-crohns-disease-and-ulcerative-colitis-302272206.html,https://images.financialmodelingprep.com/news/tremfya-guselkumab-demonstrates-impressive-results-across-biologicnave-and-biologicrefractory-20241010.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-10 04:42:00,2024-10-10T04:42:00-04:00,2024-10-10,Johnson & Johnson submits application to the European Medicines Agency for DARZALEX® (daratumumab) SC-based quadruplet regimen for newly diagnosed multiple myeloma patients,Submission supported by data from the Phase 3 CEPHEUS study for the treatment of patients with newly diagnosed multiple myeloma for whom transplant is not planned as initial therapy1,globenewswire.com,https://www.globenewswire.com/news-release/2024/10/10/2961071/0/en/Johnson-Johnson-submits-application-to-the-European-Medicines-Agency-for-DARZALEX-daratumumab-SC-based-quadruplet-regimen-for-newly-diagnosed-multiple-myeloma-patients.html,https://images.financialmodelingprep.com/news/johnson-johnson-submits-application-to-the-european-medicines-agency-20241010.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-11 17:19:17,2024-10-11T17:19:17-04:00,2024-10-11,Johnson & Johnson Q3 Earnings Preview: Dividend Dependability And Steady Growth,"Johnson & Johnson's Q3 2024 earnings report will highlight its MedTech division, driven by strategic acquisitions and R&D investments in cardiovascular and orthopedic solutions. Despite lagging behind the S&P in price growth, JNJ offers a solid income investment with a 3.09% dividend yield and steady financials. Risks include short-term costs from acquisitions, supply chain issues in the Vision division, and external pressures like currency fluctuations and competition.",seekingalpha.com,https://seekingalpha.com/article/4726295-johnson-and-johnson-q3-earnings-preview-dividend-dependability-and-steady-growth,https://images.financialmodelingprep.com/news/johnson-johnson-q3-earnings-preview-dividend-dependability-and-steady-20241011.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-11 13:35:41,2024-10-11T13:35:41-04:00,2024-10-11,Retirees: Focus on Dividend Growth With These 3 Stocks,Dividend stocks are among the top assets long-term investors want to consider when it comes to building a stable income-generating portfolio over time.,247wallst.com,https://247wallst.com/personal-finance/2024/10/11/retirees-focus-on-dividend-growth-with-these-3-stocks/,https://images.financialmodelingprep.com/news/retirees-focus-on-dividend-growth-with-these-3-stocks-20241011.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-11 07:00:56,2024-10-11T07:00:56-04:00,2024-10-11,What Trends Will Drive Johnson & Johnson's Q3 Results?,"Johnson & Johnson stock (NYSE: JNJ) will report its Q3 2024 results on Tuesday, October 15. We expect the company to post revenue of $22.2 billion and earnings of $2.20 per share, broadly aligning with the consensus estimates of $22.1 billion and $2.19, respectively.",forbes.com,https://www.forbes.com/sites/greatspeculations/2024/10/11/what-trends-will-drive-johnson--johnsons-q3-results/,https://images.financialmodelingprep.com/news/what-trends-will-drive-johnson-johnsons-q3-results-20241011.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-11 05:10:38,2024-10-11T05:10:38-04:00,2024-10-11,What You Need to Know Ahead of Johnson & Johnson's Earnings,"Johnson & Johnson (JNJ) reports earnings Tuesday morning for the third quarter, with analysts expecting the company's revenue and profit to rise year-on-year.",investopedia.com,https://www.investopedia.com/what-you-need-to-know-ahead-of-johnson-and-johnson-s-earnings-q3-fy-2024-preview-8725081,https://images.financialmodelingprep.com/news/what-you-need-to-know-ahead-of-johnson-johnsons-20241011.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-14 13:48:17,2024-10-14T13:48:17-04:00,2024-10-14,Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call,"Johnson & Johnson JNJ will release earnings results for its third quarter before the opening bell on Tuesday, Oct. 15.",benzinga.com,https://www.benzinga.com/news/earnings/24/10/41318794/johnson-johnson-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnin,https://images.financialmodelingprep.com/news/johnson-johnson-earnings-are-imminent-these-most-accurate-analysts-20241014.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-14 10:14:40,2024-10-14T10:14:40-04:00,2024-10-14,"Johnson & Johnson Preps For Q3 Earnings As MedTech Expands, But Stock Sends Mixed Signals",Johnson & Johnson JNJ is set to announce its third quarter earnings on Oct. 15 before the market opens. Wall Street is expecting the pharmaceutical and healthcare giant to post earnings per share (EPS) of $2.21 and revenue of $22.16 billion.,benzinga.com,https://www.benzinga.com/general/biotech/24/10/41313932/johnson-johnson-preps-for-q3-earnings-as-medtech-expands-but-stock-sends-mixed-signals,https://images.financialmodelingprep.com/news/johnson-johnson-preps-for-q3-earnings-as-medtech-expands-20241014.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-14 07:01:37,2024-10-14T07:01:37-04:00,2024-10-14,Best Pharma Stocks for Long-Term Investors: Growth and Dividends,"The size of the pharmaceutical industry in the U.S. in 2023 was estimated to be nearly $575 billion, with an anticipated compound growth rate of about 5.5% through 2030. This key component of the healthcare sector includes both small biotech firms working to develop specialized treatments and much larger, established companies engaging in a wide array of health-related operations.",marketbeat.com,https://www.marketbeat.com/stock-ideas/best-pharma-stocks-for-long-term-investors-growth-and-dividends/,https://images.financialmodelingprep.com/news/best-pharma-stocks-for-longterm-investors-growth-and-dividends-20241014.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 19:05:00,2024-10-15T19:05:00-04:00,2024-10-15,Connecticut Jury Delivers $15 Million Asbestos Verdict Against Johnson & Johnson,"BRIDGEPORT, Conn.--(BUSINESS WIRE)--A Bridgeport jury has awarded Evan Plotkin and his wife Martha Barry-Plotkin $15 million in a verdict against pharmaceutical giant Johnson & Johnson (NYSE:JNJ) and several subsidiaries for damage linked to asbestos in the company's talc-based Baby Powder. “This trial demonstrated once again that J&J knew its products would cause harm, but they chose to do the wrong thing time and time again,” said Mr. Plotkin's attorney, Ben Braly of Dean Omar Branham.",businesswire.com,https://www.businesswire.com/news/home/20241015237513/en/Connecticut-Jury-Delivers-15-Million-Asbestos-Verdict-Against-Johnson-Johnson/,https://images.financialmodelingprep.com/news/connecticut-jury-delivers-15-million-asbestos-verdict-against-johnson-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 15:45:41,2024-10-15T15:45:41-04:00,2024-10-15,"J&J must pay $15 mln to Connecticut man who says its talc gave him cancer, jury finds","Johnson & Johnson must pay $15 million to a Connecticut man who alleges that he developed mesothelioma, a rare form of cancer, as a result of using the company's talc powder for decades, a jury found on Tuesday.",reuters.com,https://www.reuters.com/legal/jj-must-pay-15-mln-connecticut-man-who-says-its-talc-gave-him-cancer-jury-finds-2024-10-15/,https://images.financialmodelingprep.com/news/jj-must-pay-15-mln-to-connecticut-man-who-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 15:30:12,2024-10-15T15:30:12-04:00,2024-10-15,"3-Stock Lunch: UnitedHealth, Johnson & Johnson & Wolfspeed","Jay Hatfield, Infra-Cap CEO, joins 'Power Lunch' to discuss stock plays for three stocks.",youtube.com,https://www.youtube.com/watch?v=5SjOArwK-xs,https://images.financialmodelingprep.com/news/3stock-lunch-unitedhealth-johnson-johnson-wolfspeed-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 14:20:14,2024-10-15T14:20:14-04:00,2024-10-15,Are JNJ's mergers and acquisitions weighing down company's performance?,"Johnson & Johnson (JNJ) stock is experiencing a positive trading day following the announcement of its Q3 results for 2024. The earnings per share (EPS) surpassed estimates, although improved business performance was overshadowed by the recent acquisition of V-Wave, a cardiac device company.",invezz.com,https://invezz.com/news/2024/10/15/are-jnjs-mergers-and-acquisitions-weighing-down-companys-performance/,https://images.financialmodelingprep.com/news/are-jnjs-mergers-and-acquisitions-weighing-down-companys-performance-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 14:14:24,2024-10-15T14:14:24-04:00,2024-10-15,Nasdaq Down 150 Points; Johnson & Johnson Reports Better-Than-Expected Q3 Results,"U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 150 points on Tuesday.",benzinga.com,https://www.benzinga.com/markets/equities/24/10/41341975/nasdaq-down-150-points-johnson-johnson-reports-better-than-expected-q3-results,https://images.financialmodelingprep.com/news/nasdaq-down-150-points-johnson-johnson-reports-betterthanexpected-q3-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 12:51:34,2024-10-15T12:51:34-04:00,2024-10-15,"J&J beats Q3 earnings estimates, raises full-year sales guidance",Johnson & Johnson (NYSE:JNJ) shares moved higher after the pharmaceutical giant posted better-than-expected results for the third quarter. Earnings per share (EPS) of $2.42 were down from $2.66 in the year-ago quarter but topped estimates of $2.22.,proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1058388,https://images.financialmodelingprep.com/news/jj-beats-q3-earnings-estimates-raises-fullyear-sales-guidance-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 12:31:03,2024-10-15T12:31:03-04:00,2024-10-15,Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript,"Johnson & Johnson (NYSE:JNJ ) Q3 2024 Earnings Conference Call October 15, 2024 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman & Chief Executive Officer Joe Wolk - Executive Vice President, Chief Financial Officer Erik Haas - Head, Worldwide Litigation Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech Jennifer Taubert - Executive Vice President, Worldwide Chairman, Innovative Medicine John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Chris Schott - JPMorgan Larry Biegelsen - Wells Fargo Louise Chen - Cantor Fitzgerald Terence Flynn - Morgan Stanley Danielle Antalffy - UBS Shagun Singh - RBC Capital Markets Vamil Divan - Guggenheim Securities Jayson Bedford - Raymond James Operator Good morning, and welcome to Johnson & Johnson's Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.",seekingalpha.com,https://seekingalpha.com/article/4726920-johnson-and-johnson-jnj-q3-2024-earnings-call-transcript,https://images.financialmodelingprep.com/news/johnson-johnson-jnj-q3-2024-earnings-call-transcript-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 12:30:26,2024-10-15T12:30:26-04:00,2024-10-15,"J&J Beats on Q3 Earnings, Raises Sales View but Cuts EPS Guidance",JNJ beats estimates for third-quarter earnings and sales. It lowers earnings expectations for 2024 but raises the sales guidance range.,zacks.com,https://www.zacks.com/stock/news/2350818/j-j-beats-on-q3-earnings-raises-sales-view-but-cuts-eps-guidance?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2350818,https://images.financialmodelingprep.com/news/jj-beats-on-q3-earnings-raises-sales-view-but-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 11:54:32,2024-10-15T11:54:32-04:00,2024-10-15,"J&J CFO Wolk on Product Pipeline, Strategy and Talc Lawsuit","Johnson & Johnson CFO Joseph Wolk discusses the company's product pipeline, acquisition strategy and the latest on the talc baby powder lawsuit on ""Bloomberg Open Interest."" J&J reported stronger-than-expected third-quarter earnings, driven by surging sales of cancer medicine Darzalex.",youtube.com,https://www.youtube.com/watch?v=_n9XU3998Q0,https://images.financialmodelingprep.com/news/jj-cfo-wolk-on-product-pipeline-strategy-and-talc-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 10:47:38,2024-10-15T10:47:38-04:00,2024-10-15,"How to play biotech stocks: Johnson & Johnson, Pfizer","Goldman Sachs senior biotechnology analyst in global investment research Chris Shibutani joins Market Domination Hosts Julie Hyman and Josh Lipton to break down how to play biotech and pharmaceutical stocks. Johnson & Johnson reports earnings on Tuesday, which Shibutani says “typically kicks off earnings season for healthcare, but also for the large-cap pharmas.",youtube.com,https://www.youtube.com/watch?v=lSKoRv4wyq8,https://images.financialmodelingprep.com/news/how-to-play-biotech-stocks-johnson-johnson-pfizer-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 10:44:08,2024-10-15T10:44:08-04:00,2024-10-15,Blue Chip Faces Off With Resistance After Earnings,"Shares of Johnson & Johnson (NYSE:JNJ) are up 2.4% to trade at $165.43 this morning, after the company posted a third-quarter beat and hiked its full-year revenue guidance.",schaeffersresearch.com,https://www.schaeffersresearch.com/content/news/2024/10/15/blue-chip-faces-off-with-resistance-after-earnings,https://images.financialmodelingprep.com/news/blue-chip-faces-off-with-resistance-after-earnings-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 10:35:56,2024-10-15T10:35:56-04:00,2024-10-15,Johnson & Johnson Posts Weaker-Than-Expected Profit on Billions in Legal Costs,"Johnson & Johnson (JNJ) posted better sales than expected for the third quarter, but profit fell short of analysts' estimates as the company reported billions in one-time expenses like legal costs and acquisitions.",investopedia.com,https://www.investopedia.com/johnson-and-johnson-posts-weaker-than-expected-profit-on-billions-in-legal-costs-8728064,https://images.financialmodelingprep.com/news/johnson-johnson-posts-weakerthanexpected-profit-on-billions-in-legal-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 10:31:24,2024-10-15T10:31:24-04:00,2024-10-15,Johnson & Johnson (JNJ) Reports Q3 Earnings: What Key Metrics Have to Say,"While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",zacks.com,https://www.zacks.com/stock/news/2350578/johnson-johnson-jnj-reports-q3-earnings-what-key-metrics-have-to-say?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm-2350578,https://images.financialmodelingprep.com/news/johnson-johnson-jnj-reports-q3-earnings-what-key-metrics-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 10:01:46,2024-10-15T10:01:46-04:00,2024-10-15,Johnson & Johnson Q3: Strengthening Cardiovascular Device Portfolio,"I reiterate a “Buy” rating for Johnson & Johnson, driven by their robust cardiovascular device portfolio and recent acquisitions, with a fair value of $195 per share. The acquisition of V-Wave enhances Johnson & Johnson's MedTech business, opening new opportunities in the high-growth heart failure device market. Johnson & Johnson's Q3 results exceeded expectations, with 26.5% year-over-year growth in the cardiovascular market and a 5.4% adjusted operational revenue growth.",seekingalpha.com,https://seekingalpha.com/article/4726852-johnson-and-johnson-q3-strengthening-cardiovascular-device-portfolio,https://images.financialmodelingprep.com/news/johnson-johnson-q3-strengthening-cardiovascular-device-portfolio-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 08:37:38,2024-10-15T08:37:38-04:00,2024-10-15,J&J CFO Joseph Wolk on Q3 results: Earnings beat driven by pharmaceuticals,"Johnson & Johnson executive vice president and CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings results, R&D investment, growth outlook, state of the company's talc settlement, and more.",youtube.com,https://www.youtube.com/watch?v=kZRYdihNsg8,https://images.financialmodelingprep.com/news/jj-cfo-joseph-wolk-on-q3-results-earnings-beat-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 08:35:37,2024-10-15T08:35:37-04:00,2024-10-15,Johnson & Johnson (JNJ) Tops Q3 Earnings and Revenue Estimates,"Johnson & Johnson (JNJ) came out with quarterly earnings of $2.42 per share, beating the Zacks Consensus Estimate of $2.22 per share. This compares to earnings of $2.66 per share a year ago.",zacks.com,https://www.zacks.com/stock/news/2350389/johnson-johnson-jnj-tops-q3-earnings-and-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2350389,https://images.financialmodelingprep.com/news/johnson-johnson-jnj-tops-q3-earnings-and-revenue-estimates-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 08:00:00,2024-10-15T08:00:00-04:00,2024-10-15,Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study,"First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied  SAVANNAH, Ga. , Oct. 15, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChRa positive adolescents (aged 12 – 17 years) living with generalized myasthenia gravis (gMG).",prnewswire.com,https://www.prnewswire.com/news-releases/nipocalimab-demonstrates-sustained-disease-control-in-adolescents-living-with-generalized-myasthenia-gravis-in-phase-23-study-302276365.html,https://images.financialmodelingprep.com/news/nipocalimab-demonstrates-sustained-disease-control-in-adolescents-living-with-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 07:18:00,2024-10-15T07:18:00-04:00,2024-10-15,Johnson & Johnson stock rises on Q3 sales beat and guidance raise,Johnson & Johnson shares rose 0.7% in premarket trades Tuesday after the drugmaker reported better-than-expected third-quarter sales and raised full-year revenue guidance.,marketwatch.com,https://www.marketwatch.com/story/johnson-johnson-stock-rises-on-q3-sales-beat-and-guidance-raise-846aaaee,https://images.financialmodelingprep.com/news/johnson-johnson-stock-rises-on-q3-sales-beat-and-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 06:25:00,2024-10-15T06:25:00-04:00,2024-10-15,Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2024,"NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2024 of $1.24 per share on the company's common stock. The dividend is payable on December 10, 2024 to shareholders of record at the close of business on November 26, 2024. The ex-dividend date is November 26, 2024. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcar.",businesswire.com,https://www.businesswire.com/news/home/20241015885690/en/Johnson-Johnson-Announces-Quarterly-Dividend-for-Fourth-Quarter-2024/,https://images.financialmodelingprep.com/news/johnson-johnson-announces-quarterly-dividend-for-fourth-quarter-2024-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 06:22:42,2024-10-15T06:22:42-04:00,2024-10-15,"J&J lifts profit and sales forecasts, beats Wall Street expectations",Johnson & Johnson raised its 2024 profit and sales forecasts on Tuesday after reporting strong sales of oncology drugs and quarterly results that beat Wall Street expectations.,reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/jj-lifts-profit-sales-forecasts-beats-wall-street-expectations-2024-10-15/,https://images.financialmodelingprep.com/news/jj-lifts-profit-and-sales-forecasts-beats-wall-street-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-15 06:20:00,2024-10-15T06:20:00-04:00,2024-10-15,Johnson & Johnson Reports Q3 2024 Results,"NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2024. “Johnson & Johnson's strong results in the third quarter reflect the unique breadth of our business and commitment to delivering the next wave of healthcare innovation,” said Joaquin Duato, Chairman and Chief Executive Officer. “During the quarter, we advanced our pipeline with regulatory approvals for TREMFYA and RYBREVANT, submitted an IDE for our general surgery robotic.",businesswire.com,https://www.businesswire.com/news/home/20241014447723/en/Johnson-Johnson-Reports-Q3-2024-Results/,https://images.financialmodelingprep.com/news/johnson-johnson-reports-q3-2024-results-20241015.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-16 07:45:08,2024-10-16T07:45:08-04:00,2024-10-16,Johnson & Johnson Stock: Setting the Stage for 2025 Highs,"Johnson & Johnson's NYSE: JNJ stock price advance has been reinvigorated. The stock price rally stalled a few years ago due to the COVID-19 bubble bursting and the divestiture of Kenvue NYSE: KVUE, but those days are behind, and business growth is still ahead.",marketbeat.com,https://www.marketbeat.com/originals/johnson-and-johnson-stock-setting-the-stage-for-2025-highs/,https://images.financialmodelingprep.com/news/johnson-johnson-stock-setting-the-stage-for-2025-highs-20241016.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-16 05:27:00,2024-10-16T05:27:00-04:00,2024-10-16,"Johnson & Johnson Beats Wall Street Estimates. Is It Time to Buy, Sell, or Hold?","Third-quarter results exceeded estimates, but the company also lowered overall earnings expectations for 2024.",fool.com,https://www.fool.com/investing/2024/10/16/johnson-johnson-beats-wall-street-estimates-again/,https://images.financialmodelingprep.com/news/johnson-johnson-beats-wall-street-estimates-is-it-time-20241016.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-17 13:59:39,2024-10-17T13:59:39-04:00,2024-10-17,Johnson & Johnson Stock: Setting the Stage for 2025 Highs,"Johnson & Johnson's JNJ stock price advance has been reinvigorated. The stock price rally stalled a few years ago due to the COVID-19 bubble bursting and the divestiture of Kenvue KVUE, but those days are behind, and business growth is still ahead.",benzinga.com,https://www.benzinga.com/general/biotech/24/10/41378028/johnson-johnson-stock-setting-the-stage-for-2025-highs,https://images.financialmodelingprep.com/news/johnson-johnson-stock-setting-the-stage-for-2025-highs-20241017.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-17 13:11:15,2024-10-17T13:11:15-04:00,2024-10-17,"ETFs in Focus Post JNJ Q3 Earnings Beat, Target Price Hike",Johnson & Johnson infused positive optimism after posting solid third-quarter 2024 earnings. A few analysts raised their target price on the stock.,zacks.com,https://www.zacks.com/stock/news/2352605/etfs-in-focus-post-jnj-q3-earnings-beat-target-price-hike?cid=CS-STOCKNEWSAPI-FT-etf_news_and_commentary-2352605,https://images.financialmodelingprep.com/news/etfs-in-focus-post-jnj-q3-earnings-beat-target-20241017.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-17 07:00:28,2024-10-17T07:00:28-04:00,2024-10-17,What's Next For Johnson & Johnson Stock?,"Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates. The company reported revenue of $22.5 billion and adjusted earnings of $2.42 per share, compared to our estimates of $22.2 billion and $2.20, respectively.",forbes.com,https://www.forbes.com/sites/greatspeculations/2024/10/17/whats-next-for-johnson--johnson-stock/,https://images.financialmodelingprep.com/news/whats-next-for-johnson-johnson-stock-20241017.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-17 04:14:00,2024-10-17T04:14:00-04:00,2024-10-17,This Magnificent Dividend Stock Is as Healthy as It Gets,Johnson & Johnson's latest financial checkup shows it's still in excellent health.,fool.com,https://www.fool.com/investing/2024/10/17/this-magnificent-dividend-stock-is-as-healthy-as-i/,https://images.financialmodelingprep.com/news/this-magnificent-dividend-stock-is-as-healthy-as-it-20241017.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-18 14:34:54,2024-10-18T14:34:54-04:00,2024-10-18,BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug,"BofA Securities has upgraded Tyra Biosciences TYRA, a clinical-stage biotechnology company focused on developing next-generation precision medicines.",benzinga.com,https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41409413/bofa-upgrades-tyra-biosciences-as-investors-focus-on-preclinical-data-amid-high-ben,https://images.financialmodelingprep.com/news/bofa-upgrades-tyra-biosciences-as-investors-focus-on-preclinical-20241018.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-18 10:20:22,2024-10-18T10:20:22-04:00,2024-10-18,"J&J's Q3 Earnings & Sales Top: Time to Buy, Sell or Hold the Stock?",JNJ beats third-quarter estimates for both earnings and sales. Those who already own J&J's stock may stay invested.,zacks.com,https://www.zacks.com/stock/news/2353004/j-j-s-q3-earnings-sales-top-time-to-buy-sell-or-hold-the-stock?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2353004,https://images.financialmodelingprep.com/news/jjs-q3-earnings-sales-top-time-to-buy-sell-20241018.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-18 05:10:00,2024-10-18T05:10:00-04:00,2024-10-18,3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now,These stocks could deliver big over the long term.,fool.com,https://www.fool.com/investing/2024/10/18/3-no-brainer-pharmaceutical-stocks-to-buy-with-500/,https://images.financialmodelingprep.com/news/3-nobrainer-pharmaceutical-stocks-to-buy-with-500-right-now-20241018.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-19 17:40:00,2024-10-19T17:40:00-04:00,2024-10-19,"All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $300 in Passive Income Per Year",Investors looking for dividend stocks at reasonable valuations have come to the right place.,fool.com,https://www.fool.com/investing/2024/10/19/all-it-takes-is-2500-invested-in-each-of-these-3-h/,https://images.financialmodelingprep.com/news/all-it-takes-is-2500-invested-in-each-of-20241019.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-19 09:57:00,2024-10-19T09:57:00-04:00,2024-10-19,Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever,These companies' longtime shareholders have generally been rewarded.,fool.com,https://www.fool.com/investing/2024/10/19/want-decades-of-passive-income-2-stocks-to-buy-now/,https://images.financialmodelingprep.com/news/want-decades-of-passive-income-2-stocks-to-buy-20241019.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-19 08:44:21,2024-10-19T08:44:21-04:00,2024-10-19,Johnson & Johnson: Q3 Earnings Highlights Resilience And New Growth,"J&J's Q3 2024 earnings beat expectations with $22.5B in revenue, driven by strong performances from Darzalex, STELARA, and MedTech, despite ongoing challenges. The company updated its full-year guidance, showing optimism despite headwinds like talc litigation and STELARA generic competition, maintaining strong cash flow and dividend payouts. New growth opportunities in oncology and MedTech segments, along with strategic acquisitions, are expected to offset potential declines in STELARA sales due to generics.",seekingalpha.com,https://seekingalpha.com/article/4727827-johnson-and-johnson-q3-earnings-highlights-resilience-and-new-growth,https://images.financialmodelingprep.com/news/johnson-johnson-q3-earnings-highlights-resilience-and-new-growth-20241019.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-23 11:15:00,2024-10-23T11:15:00-04:00,2024-10-23,"Johnson & Johnson Preferred Financing, Inc. Implements 2iG's PFC Insight","PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- 2iG Solutions, Inc. (2iG or 2iG Solutions), provider of leading-edge data analytics and artificial intelligence (AI) reporting software, is pleased to announce that South Carolina-based premium finance company Johnson & Johnson Preferred Financing (JJPF), Inc. has successfully implemented the PFC Insight solution. Today, it is difficult for premium finance companies (PFC) to acquire intelligence to improve efficiency.",globenewswire.com,https://www.globenewswire.com/news-release/2024/10/23/2967999/0/en/Johnson-Johnson-Preferred-Financing-Inc-Implements-2iG-s-PFC-Insight.html,https://images.financialmodelingprep.com/news/johnson-johnson-preferred-financing-inc-implements-2igs-pfc-insight-20241023.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-23 10:05:18,2024-10-23T10:05:18-04:00,2024-10-23,Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know,"Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",zacks.com,https://www.zacks.com/stock/news/2355590/investors-heavily-search-johnson-johnson-jnj-here-is-what-you-need-to-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2355590,https://images.financialmodelingprep.com/news/investors-heavily-search-johnson-johnson-jnj-here-is-what-20241023.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-24 18:00:00,2024-10-24T18:00:00-04:00,2024-10-24,Two Strategic Dividend Picks: One For Dividend Income And One For Dividend Growth,"I have added Brookfield Renewable Partners and Linde to The Dividend Income Accelerator Portfolio, increasing the portfolio's allocation to the Materials and the Utilities Sectors. After their inclusions, the portfolio's Weighted Average Dividend Yield [TTM] stands at 4.32% and its 5-Year Weighted Average Dividend Growth Rate [CAGR] at 7.25%. Berkshire Hathaway (accounting for 6.58% of the portfolio), BlackRock (4.48%), Apple (4.30%), Johnson & Johnson (4.00%) and Realty Income (3.91%) represent the largest positions of our dividend portfolio.",seekingalpha.com,https://seekingalpha.com/article/4728455-two-strategic-dividend-picks-one-for-dividend-income-and-one-for-dividend-growth,https://images.financialmodelingprep.com/news/two-strategic-dividend-picks-one-for-dividend-income-and-20241024.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-24 08:49:58,2024-10-24T08:49:58-04:00,2024-10-24,These 13 Stocks Are True Dividend Kings,24/7 Wall Street Insights Dividend Kings are companies with an unbroken track record of dividend increases spanning a minimum of 50 consecutive years.,247wallst.com,https://247wallst.com/investing/2024/10/24/these-13-stocks-are-true-dividend-kings/,https://images.financialmodelingprep.com/news/these-13-stocks-are-true-dividend-kings-20241024.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-24 08:00:00,2024-10-24T08:00:00-04:00,2024-10-24,Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress,"New five-year data reinforce long-term safety and efficacy of SPRAVATO® (esketamine) in patients with inadequate response to two or more oral antidepressants (treatment-resistant depression)   23 abstracts highlight data from Company's robust portfolio and pipeline, including clinical insights on major depressive disorder and the significant burden of anhedonia and insomnia symptoms Large real-world analysis highlights the link between reducing relapse and improving survival in schizophrenia TITUSVILLE, N.J. , Oct. 24, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that 23 abstracts featuring new real-world and clinical trial data from across its neuropsychiatry portfolio and pipeline will be presented at the annual U.S. Psychiatric and Mental Health Congress (Psych Congress), taking place October 29 to November 2 in Boston, Massachusetts.",prnewswire.com,https://www.prnewswire.com/news-releases/johnson--johnson-highlights-innovative-neuropsychiatry-portfolio-and-pipeline-at-psych-congress-302285418.html,https://images.financialmodelingprep.com/news/johnson-johnson-highlights-innovative-neuropsychiatry-portfolio-and-pipeline-at-20241024.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-25 08:05:00,2024-10-25T08:05:00-04:00,2024-10-25,New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis,"First-of-its-kind Phase 3b study shows TREMFYA ® achieved statistical significance across all primary and secondary endpoints in low body surface area psoriasis with special site involvement Johnson & Johnson launches library of clinical images from Phase 3b VISIBLE study to enhance clinical decision making for people across all skin tones living with moderate to severe plaque psoriasis LAS VEGAS , Oct. 25, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that treatment with TREMFYA® (guselkumab) resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment. Sensitive or highly visible areas affected by PsO, including the scalp, face, skin folds and genitals, are considered ""special sites"" and can have significant impact on patients' daily lives, yet systemic treatment is infrequently provided and this group of patients remains largely undertreated.1 Data from the Phase 3b SPECTREM study, the first prospective, large-scale, randomized-controlled, double-blind clinical study to measure skin clearance and other treatment outcomes in low BSA moderate PsO with involvement across four special sites (scalp, face, skin folds and genitals) and previous topical treatment failure, were presented today at the 2024 Fall Clinical Dermatology Conference.",prnewswire.com,https://www.prnewswire.com/news-releases/new-spectrem-study-findings-reveal-tremfya-guselkumab-effectively-clears-overlooked-and-undertreated-plaque-psoriasis-302287251.html,https://images.financialmodelingprep.com/news/new-spectrem-study-findings-reveal-tremfya-guselkumab-effectively-clears-20241025.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-26 07:30:00,2024-10-26T07:30:00-04:00,2024-10-26,3 Dividend Growth Stocks You Can Buy and Hold Forever,These healthcare stocks have fantastic dividend track records.,fool.com,https://www.fool.com/investing/2024/10/26/3-dividend-growth-stocks-you-can-buy-and-hold-fore/,https://images.financialmodelingprep.com/news/3-dividend-growth-stocks-you-can-buy-and-hold-20241026.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-28 07:30:00,2024-10-28T07:30:00-04:00,2024-10-28,TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease,"A greater number of patients treated with subcutaneous TREMFYA® induction and maintenance achieved clinical and endoscopic remission at 48 weeks in the Phase 3 GRAVITI study versus placebo TREMFYA ® could become the first IL-23 treatment to offer both a subcutaneous and intravenous (IV) induction regimen for patients living with Crohn's disease (CD), pending FDA approval PHILADELPHIA , Oct. 28, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results from the Phase 3 GRAVITI study of TREMFYA® (guselkumab), the first and only IL-23 inhibitor, demonstrating robust results in subcutaneous (SC) induction and maintenance therapy. The findings demonstrated significant clinical remission and endoscopic response at 48 weeks in adults with moderately to severely active CD.1 These results are among the 14 Johnson & Johnson abstracts presented at the American College of Gastroenterology (ACG) 2024, October 25-30.",prnewswire.com,https://www.prnewswire.com/news-releases/tremfya-guselkumab-is-the-first-and-only-il-23-inhibitor-to-demonstrate-robust-results-with-a-fully-subcutaneous-regimen-in-both-induction-and-maintenance-in-crohns-disease-302288042.html,https://images.financialmodelingprep.com/news/tremfya-guselkumab-is-the-first-and-only-il23-inhibitor-20241028.jpg
JNJ,2024-10-15,2024-10-01,2024-10-29,JNJ,,2024-10-28 07:15:00,2024-10-28T07:15:00-04:00,2024-10-28,"If I Could Own Only 4 Stocks In Retirement, It Would Be These","For retirees, I advise to own high-quality assets that balance growth, income, and stability. My preferred asset allocation includes 70% in equities and dividend-focused ETFs, 20% in short-duration fixed-income assets, and 10% in liquid savings. For equities, I prioritize blue-chip stocks with consistent dividend growth and non-cyclical earnings, which help offset market fluctuations and inflation pressures and ensure steady retirement income.",seekingalpha.com,https://seekingalpha.com/article/4730013-if-i-could-own-only-4-stocks-in-retirement-it-would-be-these,https://images.financialmodelingprep.com/news/if-i-could-own-only-4-stocks-in-retirement-20241028.jpg
